Prostate Cancer and Metastatic Castration-Resistant Disease
Fundacion Oncosur is active in clinical research for prostate cancer, with a strong focus on metastatic castration-resistant prostate cancer and aggressive disease variants. Its studies examine treatment strategies for patients whose disease has progressed after prior hormonal therapy.
- Metastatic castration-resistant prostate cancer
- Aggressive variant prostate cancer
- Androgen receptor–targeted therapy
The research portfolio includes combinations involving immunotherapy, platinum-based chemotherapy, and PARP inhibition in advanced prostate malignancy.
Small Cell Lung Cancer
The sponsor also supports trials in small cell lung cancer with emphasis on disease that has progressed after platinum-based chemotherapy or prior immunochemotherapy. This area reflects interest in difficult-to-treat thoracic malignancies with limited treatment options.
- Advanced small cell lung cancer
- Post-platinum progression
- Immune checkpoint therapy
Research activity in this field includes combinations of immune checkpoint inhibition with cytotoxic agents and novel anticancer compounds.
Targeted Therapy and DNA Repair Pathways
Fundacion Oncosur is involved in studies of targeted oncology therapies, particularly approaches that combine PARP inhibitors with androgen receptor blockade in advanced prostate malignancy. This therapeutic area centers on tumors with resistance to prior endocrine treatment.
- PARP inhibition
- Androgen receptor blockade
- Resistance after abiraterone
These investigations address treatment options for DNA damage response-related vulnerability in metastatic prostate cancer.
Immuno-Oncology and Combination Treatment Strategies
The sponsor’s clinical research includes immuno-oncology combinations designed for advanced solid tumors. The funded trials explore integration of checkpoint inhibitors with chemotherapy or other antineoplastic agents in both prostate and lung cancer settings.
- Checkpoint inhibition
- Chemo-immunotherapy combinations
- Advanced solid tumors
This area reflects a therapeutic interest in improving outcomes for patients with refractory malignancies and limited standard options.
